Alert: We're here for you. Learn how COVID-19 may affect your mesothelioma treatment and cancer center visits.

New York-Presbyterian Hospital/Columbia University Medical Center

New York-Presbyterian Hospital/Columbia University Medical Center

Get in touch
Jump to a Topic:

Reputation for Excellence at New York-Presbyterian Hospital

The New York-Presbyterian Hospital/Columbia University Medical Center performs more surgeries for peritoneal mesothelioma cancer than anywhere else in the country, earning its well-deserved reputation for excellence.

Experience matters. For a rare and aggressive cancer such as mesothelioma, high volume is critical for obtaining the best possible results. New York-Presbyterian has been doing it well with innovative techniques since the mid-1990s.

“The best treatment is going to come from the high-volume practitioners,” said Dr. Michael Kluger, who leads the peritoneal mesothelioma program. “Experience is what a patient and his family should look for. You want a center with a lot of experience for your specific disease. We have that.”

New York-Presbyterian/Columbia University handles the more common pleural mesothelioma in the thoracic cavity and peritoneal mesothelioma in the abdomen.

And while therapeutic advances with pleural mesothelioma have come slowly, the advances have been significant with peritoneal.

“There is real hope for these patients now. We’re seeing excellent outcomes,” Kluger said. “Our multidisciplinary approach has done well. We know how to treat it, and we know how to follow it up. People are living a long time now when they are appropriately treated.”

New York-Presbyterian Hospital Excels at Treating Peritoneal Mesothelioma

Kluger was part of a research team at the Columbia Medical Center that recently studied the time and predictors of peritoneal mesothelioma recurrence when optimally treated.

They found a median overall survival of 6.5 years and a median, recurrence-free survival of 38.5 months, a significant improvement from a decade ago. They also had a predicted 10-year survival rate of 30 percent.

The study involved 113 patients who completed a protocol that started with a cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC), followed by a multicycle adjuvant chemotherapy regimen.

Six months after the first surgery, an exploratory procedure was done to determine if a second cytoreduction was necessary. If there was no new tumor growth, only a second HIPEC was performed.

The results emphasized the importance of long-term surveillance for peritoneal mesothelioma patients, and the knowledge that steps can be taken when recurrence happens.

“A lot of judgements have to be made during these operations. Removing too much tissue can cause too high a risk of complications. In some cases, an operation must be terminated,” Kluger said. “In other cases, we may have to remove one or more internal organs, and patients have to trust us to make the appropriate decisions during the operation. This is where experiences come into play.”

Personalized Care at New York-Presbyterian Hospital

Mesothelioma care falls under the Herbert Irving Comprehensive Cancer Center umbrella. The cancer center has a long tradition of excellence in patient care. The National Cancer Institute has recognized Herbert Irving annually as an NCI Comprehensive Cancer Center for more than 30 years.

The Herbert Irving Cancer Center, which treats more than 3,500 cancer patients each year, is known for providing a team of internationally renowned experts who create personalized treatment plans to address the physical, social and emotional needs that accompany their diagnosis.

The mesothelioma program at Herbert Irving provides innovative diagnostic procedures and top-notch therapeutic care for more than 100 patients each year.

In the mesothelioma program, Kluger works closely with medical oncologist Dr. Tito Fojo, Dr. Kazuki Sugahara, who helps design novel therapies in the laboratory, and Pegah Gheitani, a physician assistant who works closely with each patient.

Find More Top Cancer Centers

New York-Presbyterian Offers Multidisciplinary Mesothelioma Treatment

Mesothelioma patients may also benefit from the radiation oncology ward, home of the nation’s largest and most experienced research center for radiation biology. The ward offers multiple forms of external beam radiation therapy.

The radiation oncology department also offers brachytherapy, a form of radiation favored for its ability to spare healthy tissues from exposure to powerful radiation.

The clinical treatment is helped by the on-site research performed by a team of 200 physicians and laboratory assistants. The Herbert Irving Cancer Center has received more than $100 million in funding for peer-reviewed cancer research.

The 2017-2018 U.S. News & World Report Best Hospitals Honor Roll ranked New York-Presbyterian Hospital first in the New York metro area and eighth in the nation.

Mesothelioma Clinical Trials at New York-Presbyterian

  • A phase I/II clinical trial studying the use of ASTX295, a synthetic small molecule, for rare cancers like mesothelioma that have relapsed after standard-of-care treatment.

Learn More About Mesothelioma Treatment in New York

Disclaimer: New York-Presbyterian Hospital/Columbia University Medical Center has no professional affiliation with

Stethoscope Icon
Get Help Contacting this Cancer Center

We value your privacy. By submitting, you agree to our privacy policy and disclaimer.

stethoscope icon
Get Help Contacting this Doctor

We value your privacy. By submitting, you agree to our privacy policy and disclaimer.

Get Free Recipes for Mesothelioma Patients

Get Your Guide Mesothelioma Packet

Get the Top Mesothelioma Guide for Free

Get Yours Now

Get the Compensation You Deserve

Find an Attorney

Senior Content Writer

Tim Povtak is an award-winning writer with more than 30 years of reporting national and international news. His specialty is interviewing top mesothelioma specialists and researchers, reporting the latest news at mesothelioma cancer centers and talking with survivors and caregivers.

Walter Pacheco, Managing Editor at
Edited by

3 Cited Article Sources

The sources on all content featured in The Mesothelioma Center at include medical and scientific studies, peer-reviewed studies and other research documents from reputable organizations.

  1. (2020, May 28). Study of ASTX295 in patients with Solid Tumors With Wild-Type p53. Retrieved from:
  2. Columbia University Medical Center (2014). Cytoreduction Surgery and Heated Intraperitoneal Chemotherapy. Retrieved from:
  3. Columbia University Medical Center (n.d.). Herbert Irving Comprehensive Cancer Center. Retrieved from:

Did this article help you?

Did this article help you?

Thank you for your feedback. Would you like to speak with a Patient Advocate?

Share this article

Last Modified August 20, 2020

Get Your Free Mesothelioma Guide Chat live with a patient advocate now